齐拉西酮胶囊与利培酮治疗精神分裂症疗效的比较

A comparison of ziprasidone and risperidone on treating schizophrenia

目的探讨国产齐拉西酮胶囊治疗精神分裂症的疗效及不良反应。方法将120例精神分裂症患者随机分为齐拉西酮胶囊组(60例)和利培酮组(60例),进行临床对照试验,两组药物治疗剂量分别为80～160mg/d和3～6mg/d,疗程8周。疗效指标包括阳性和阴性症状量表(PANSS)及临床总体印象量表(CGI),不良反应指标为不良反应症状量表(TESS)及有关实验室检查。结果治疗结束时,两组PANSS评分较入组时均显著减低(P<0.01)。PANSS总减分率:齐拉西酣组为(52.6±10.2)%,利培酮组为(71.8±1.6)%;临床总有效率:齐拉西酮胶囊组73.3%,利培酮组91.7%,两组间疗效有显著性差异(P<0.05)。齐拉西酮胶囊组和利培酮组的总体不良反应无明显差异,但不良反应表现存在异同。结论国产齐拉西酮胶囊治疗精神分裂症是一种有效、安全药物,虽然疗效稍逊于利培酮,但不良反应与利培酮表现方面有不同,对患者选择用药及个体化治疗有指导作用。

Objective To explore domestic ziprasidone treatment on schizophrenia and the side effects. Methods Total 120 cases of patients with schizophrenia were randomly divided into Ziprasidone group （60cases） and Risperidone group（60cases）. Carries on the clinical check experiment, Two groups of medicines therapeutic dose respectively was 80 - 160 mg/d and 3 - 6 mg/d, the treatment course was 8 weeks. Indicators included the effect of positive and negative symptom scale （PANSS） and overall clinical impression scale （ CGI）, adverse reactions indicators for adverse reactions Symptom Rating Scale （TESS） and the laboratory. Resuits At the end of treatment, PANSS score in the two groups were significantly reduced （P 〈 0.01 ）. By PANSS total points ： Ziprasidone roup （52. 6 ± 10. 2% ）, Risperidon group （ 71.8± 11.6） % ; the total efficiency ： Ziprasidone group73.3% ,91.7% of Risperidone group, difference of the two groups was significant （P 〈 0. 05）. Ziprasidone and Risperidone groups had no significant difference in the overall adverse reactions, but there were similarities and differences between the performance of adverse reactions. Conclusion Domestic Ziprasidone treatment of schizophrenia is an effective and safe drugs. Although less effct on Risperidone, but adverse reaction and Risperidone have different perfomance,with the choice of medication and individual treatment guide.